Bronchopneumonia

Paratek Pharmaceuticals Announces First Quarter 2022 Revenue of $24.9 Million

Retrieved on: 
Wednesday, May 4, 2022
Development, Disclosure, Bronchopneumonia, Risk, Annual report, Bioterrorism, Post-exposure prophylaxis, SEC, Expansion, Anthrax, Twitter, Company, Regulation, Government, Gram, U.S. Securities and Exchange Commission, Acne, Program, SG, LinkedIn, Tetracycline, Disease, Biomedical Advanced Research and Development Authority, Medicare, Insurance, Omicron, SNS, Physician, Research, ABSSSI, Security (finance), Mycobacterium, MAC, R, Public health, Bacteria, Growth, Exercise, Mycobacterium abscessus, BARDA, Regulation Fair Disclosure, Nasdaq, GLOBE, LLC, Tablet, U.S. Department of Defense Strategy for Operating in Cyberspace, Degenerative disease, NTM, Office of Inspector General, U.S. Department of Health and Human Services, Investor relations, Patient, ID, Motor vehicle, Pharmaceutical industry, Vaccine, Video game

BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today reported financial results and provided an update on corporate activities for the quarter ended March 31, 2022.

Key Points: 
  • Sales of $19.9 Million from the Core Commercial Business, a 51% Increase over First Quarter 2021
    BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today reported financial results and provided an update on corporate activities for the quarter ended March31, 2022.
  • Total revenue was $24.9 million for the first quarter of 2022, a 51% increase from $16.4 million for the same period in the prior year.
  • Total revenue for the first quarter of 2022 was comprised of the following:
    NUZYRA generated net U.S. sales of $19.9 million, a 51% increase from $13.2 million for the same period in the prior year.
  • Research and development (R&D) expenses were $7.5 million for the first quarter of 2022, compared to $5.5 million for same period in the prior year.

Nabriva Therapeutics to Report First Quarter 2022 Financial Results and Recent Corporate Highlights on May 5, 2022

Retrieved on: 
Monday, May 2, 2022
COVID-19, U.S. Securities and Exchange Commission, NASDAQ, GLOBE, Pyelonephritis, Private Securities Litigation Reform Act, Tablet, Food and Drug Administration, Cuties, Urinary tract infection, Food, Merck, ABSSSI, Patient, Infection, Review, Bronchopneumonia, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Fosfomycin, Marketing, CF, Conference, Research, Therapy, Pharmaceutical industry

ET to discuss the financial results and recent corporate highlights.

Key Points: 
  • ET to discuss the financial results and recent corporate highlights.
  • Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • In addition, the forward-looking statements included in this press release represent Nabriva Therapeutics views as of the date of this press release.
  • These forward-looking statements should not be relied upon as representing Nabriva Therapeutics views as of any date subsequent to the date of this press release.

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Monday, May 2, 2022
BARDA, Anthrax, Employment, Twitter, Nasdaq, NASDAQ, GLOBE, LLC, Development, Company, U.S. Department of Defense Strategy for Operating in Cyberspace, ABSSSI, Degenerative disease, Acne, NTM, Bronchopneumonia, Office of Inspector General, U.S. Department of Health and Human Services, Government, LinkedIn, Public health, Biomedical Advanced Research and Development Authority, Pharmaceutical industry, Vaccine

The stock options are subject to the terms and conditions of the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, and the terms and conditions of the stock option agreement covering the grant.

Key Points: 
  • The stock options are subject to the terms and conditions of the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, and the terms and conditions of the stock option agreement covering the grant.
  • Paratek is also conducting a Phase 2b Study in a rare disease, nontuberculous mycobacterial (NTM) pulmonary disease, caused by Mycobacterium abscessus complex with NUZYRA.
  • Paratek estimates this opportunity represents a potential $1 billion addressable market in the United States.
  • Paratek retains the development and commercialization rights for sarecycline in the rest of the world.

Paratek Pharmaceuticals to Report First Quarter 2022 Financial Results on May 4, 2022

Retrieved on: 
Tuesday, April 26, 2022
Anthrax, Government, NTM, Tetracycline, Degenerative disease, Bioterrorism, ABSSSI, LLC, U.S. Securities and Exchange Commission, Security (finance), Risk, Annual report, Bacteria, Mycobacterium abscessus, GLOBE, Biomedical Advanced Research and Development Authority, Office of Inspector General, U.S. Department of Health and Human Services, Bronchopneumonia, Bacillus anthracis, Development, Nasdaq, Gram, ID, Public health, Plague, Acne, BARDA, U.S. Department of Defense Strategy for Operating in Cyberspace, Pharmaceutical industry, Vaccine

ET to report its financial results for the first quarter of 2022.

Key Points: 
  • ET to report its financial results for the first quarter of 2022.
  • Domestic investors wishing to participate in the call should dial: 877-300-8521 and international investors should dial: +1-412-317-6026.
  • Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.
  • Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.

Nosocomial Pneumonia Pipeline Market Research Report 2022: Comprehensive Insights About 13+ Companies and 13+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 21, 2022
Health, Pharmaceutical, NDA, News, Bronchopneumonia, Acinetobacter baumannii, Clinical trial, Staphylococcus, Rifabutin, Half-life, Bacteria, Hospital-acquired pneumonia, II, Lung, III, Technology, Immune system, Discovery, Immunoglobulin G, Biofilm, Acquisition, Staphylococcus aureus, Therapy, S, Vaccine, Pharmaceutical industry, Antibiotics, Hospital-acquired infection

The "Nosocomial pneumonia - Pipeline Insight, 2022" report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Nosocomial pneumonia pipeline landscape.

Key Points: 
  • The "Nosocomial pneumonia - Pipeline Insight, 2022" report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Nosocomial pneumonia pipeline landscape.
  • A detailed picture of the Nosocomial pneumonia pipeline landscape is provided which includes the disease overview and Nosocomial pneumonia treatment guidelines.
  • The assessment part of the report embraces, in depth Nosocomial pneumonia commercial assessment and clinical assessment of the pipeline products under development.
  • Companies and academics are working to assess challenges and seek opportunities that could influence Nosocomial pneumonia R&D.

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Friday, April 1, 2022
Company, Bronchopneumonia, LinkedIn, Degenerative disease, ABSSSI, NASDAQ, Public health, Office of Inspector General, U.S. Department of Health and Human Services, U.S. Department of Defense Strategy for Operating in Cyberspace, Employment, Government, LLC, BARDA, Anthrax, Twitter, NTM, Nasdaq, GLOBE, Biomedical Advanced Research and Development Authority, Development, Acne, Pharmaceutical industry, Vaccine

These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, which was approved by the Company's board of directors on June 15, 2017, under Rule 5635(c)(4) of the NASDAQ Listing Rules, for equity grants to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company, as an inducement material to such individuals entering into employment with the Company.

Key Points: 
  • These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, which was approved by the Company's board of directors on June 15, 2017, under Rule 5635(c)(4) of the NASDAQ Listing Rules, for equity grants to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company, as an inducement material to such individuals entering into employment with the Company.
  • Paratek is also conducting a Phase 2b Study in a rare disease, nontuberculous mycobacterial (NTM) pulmonary disease, caused by Mycobacterium abscessus complex with NUZYRA.
  • Paratek estimates this opportunity represents a potential $1 billion addressable market in the United States.
  • Paratek retains the development and commercialization rights for sarecycline in the rest of the world.

Nabriva Therapeutics to Report 2021 Financial Results and Recent Corporate Highlights on March 29, 2022

Retrieved on: 
Tuesday, March 15, 2022
Therapy, U.S. Securities and Exchange Commission, GLOBE, Review, Food and Drug Administration, Private Securities Litigation Reform Act, Conference, COVID-19, Cuties, Infection, Bronchopneumonia, Pyelonephritis, Tablet, NASDAQ, ABSSSI, Urinary tract infection, Fosfomycin, Food, Union, Research, Complicated, Merck, CF, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Marketing, Pharmaceutical industry

ET to discuss the financial results and recent corporate highlights.

Key Points: 
  • ET to discuss the financial results and recent corporate highlights.
  • A live webcast of the conference call can be accessed through the Investors tab on the Nabriva Therapeutics website at www.nabriva.com.
  • Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • These forward-looking statements should not be relied upon as representing Nabriva Therapeutics views as of any date subsequent to the date of this press release.

Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 14, 2022

Retrieved on: 
Wednesday, March 2, 2022
EST, Gram, ID, U.S. Department of Defense Strategy for Operating in Cyberspace, Plague, Anthrax, Risk, Government, Public health, Security (finance), Annual report, U.S. Securities and Exchange Commission, Bioterrorism, International, Bacteria, Bronchopneumonia, LLC, Degenerative disease, Development, Bacillus anthracis, Office of Inspector General, U.S. Department of Health and Human Services, ABSSSI, Biomedical Advanced Research and Development Authority, Tetracycline, NTM, Acne, Nasdaq, GLOBE, BARDA, Pharmaceutical industry, Vaccine

BOSTON, March 02, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Monday, March 14 at 8:30 a.m. EST to provide a corporate update and report its financial results for fourth quarter and full year 2021.

Key Points: 
  • BOSTON, March 02, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Monday, March 14 at 8:30 a.m. EST to provide a corporate update and report its financial results for fourth quarter and full year 2021.
  • Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused onthe development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.
  • Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.
  • Paratek is also conducting a Phase 2b study in a rare disease, nontuberculous mycobacterial(NTM) pulmonary disease, caused by Mycobacterium abscessus complex with NUZYRA.

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, March 1, 2022
Employment, U.S. Department of Defense Strategy for Operating in Cyberspace, Anthrax, Twitter, Public health, Office of Inspector General, U.S. Department of Health and Human Services, Government, LinkedIn, Bronchopneumonia, LLC, Degenerative disease, Company, Development, NASDAQ, ABSSSI, Biomedical Advanced Research and Development Authority, NTM, Acne, Nasdaq, GLOBE, BARDA, Pharmaceutical industry, Vaccine

Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.

Key Points: 
  • Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.
  • Paratek is also conducting a Phase 2b Study in a rare disease, nontuberculous mycobacterial (NTM) pulmonary disease, caused by Mycobacterium abscessus complex with NUZYRA.
  • Paratek estimates this opportunity represents a potential $1 billion addressable market in the United States.
  • Paratek retains the development and commercialization rights for sarecycline in the rest of the world.

Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, March 1, 2022
GLOBE, Employment, Urinary tract infection, Bronchopneumonia, NASDAQ, Therapy, Company, Calcinosis cutis, Tablet, Food, United, Nasdaq, Merck, Pyelonephritis, Fosfomycin, Infection, Pharmaceutical industry

This grant wasawarded pursuant to the Nasdaq inducement grant exception as a component of new hire employment compensation.

Key Points: 
  • This grant wasawarded pursuant to the Nasdaq inducement grant exception as a component of new hire employment compensation.
  • The stock option was granted effective February 28, 2022 with an exercise price of $0.45 per share, which is equal to the closing price of Nabriva Therapeutics ordinary shares on the date of grant.
  • The stock option award was approved by Nabriva Therapeutics Compensation Committee and was granted as an inducement material to the new employees acceptance of employment in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The stock option is subject to the terms and conditions of a stock option agreement covering the grant and Nabriva Therapeutics 2021 Inducement Share Incentive Plan.